Protocol Ledger

NCT06353347 · Phase III · COMPLETED

Efficacy and Safety of Berberine Ursodeoxycholate (HTD1801) in Patients With Type 2 Diabetes Inadequately Controlled With Metformin

Interventional Phase III clinical trial protocol NCT06353347 sponsored by Shenzhen HighTide Biopharmaceutical in Endocrinology, Obesity, and Metabolic, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2023-11-13 Enrollment: 551 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT06353347
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)551 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)3 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06353347
Protocol FieldVerified Registry Value
NCT IdentifierNCT06353347
Consolidated Lead SponsorShenzhen HighTide Biopharmaceutical
Therapeutic Condition CohortEndocrinology, Obesity, and Metabolic
Clinical Trial PhasePhase III
Overall Recruitment StatusCOMPLETED
Registered Enrollment551 participants (ACTUAL)
Registered Start Date2023-11-13
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT06353347
Hospital Research SiteLocationSite Profile
Beijing Friendship Hospital , Capital Medical UniversityBeijing, ChinaOpen Hospital Dossier ->
Peking Union Medical College HospitalBeijing, ChinaOpen Hospital Dossier ->
Peking University People's HospitalBeijing, ChinaOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Endocrinology, Obesity, and Metabolic Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI